In today's Pharmaceutical Executive Daily, FDA approves Ennumo, a pharma roundup covers Chemomab Therapeutics' merger with AI ...

FDA’s July 2025 transparency initiative published 200+ redacted CRLs across drugs, biosimilars, and devices, offering granular insight into approvability deficiencies and review logic beyond ...

Modern biopharma firms are adapting their R&D investment strategies in response to challenges such as the impending $300 ...

Zymeworks will pay $17.00/share (~$929M) for Theravance, prioritizing Yupelri-linked profitability and planned post-close ...

Extensive background and on-study uptake of TTR stabilizers likely diluted the observable marginal effect of a TTR-silencing agent, complicating attribution of benefit in the intent-to-treat primary ...

Approval was supported by IRAKLIA Phase III non-inferiority data comparing on-body injector subcutaneous isatuximab to weight-based IV, both combined with pomalidomide and dexamethasone in R/R myeloma ...

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...

Sanofi Chief Digital Officer Emmanuel Frenehard on scaling AI across a Big Pharma global enterprise and why a strategy of ...

Resilient field models emphasize continuous territory coverage via agile deployment, blending scalable virtual reach with ...

Bansi Nagji, CEO of PANTHERx Rare, explores how innovation is increasingly directed toward rare and orphan diseases, driven ...

FDA cleared Ennumo as a Neulasta biosimilar for febrile neutropenia prophylaxis in non-myeloid malignancy patients receiving myelosuppressive chemotherapy, including pediatric populations from ...

Novartis filed New Jersey notices for 322 East Hanover layoffs starting October 2, after earlier filings for 76 cuts at the same site. Disclosures to date do not specify impacted functions, job ...